Olaf van Tellingen

List of Publications by Year
in descending order

181	13,035	26630 56	24258 110
papers	citations	h-index	g-index

184	184	184	14984
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature, 2022, 603, 721-727.	27.8	47
2	Protocol for live-cell imaging during Tumor Treating Fields treatment with Inovitro Live. STAR Protocols, 2022, 3, 101246.	1.2	3
3	Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib. Genes, 2022, 13, 1198.	2.4	1
4	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular Cancer Therapeutics, 2021, 20, 1173-1182.	4.1	6
5	Abstract PO-003: Mitotic enrichment as an efficient radiosensitization strategy. , 2021, , .		0
6	Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications. Clinica Chimica Acta, 2021, 521, 70-75.	1.1	8
7	ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Reports Medicine, 2021, 2, 100184.	6.5	32
8	MEK/MELK inhibition and bloodâ€“brain barrier deficiencies in atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 58-69.	1.2	21
9	Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nature Communications, 2020, 11, 3157.	12.8	59
10	Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15182-15192.	7.1	93
11	Comments on: â€œSynergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularityâ€• Neuro-Oncology, 2020, 22, 1404-1405.	1.2	0
12	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	7.0	44
13	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276.	1.7	17
14	Abstract 92: Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint. , 2020, , .		0
15	DDRE-32. ABC TRANSPORTERS RESTRICT THE BRAIN PENETRATION AND INTRACRANIAL EFFICACY OF ANTICANCER AGENTS EVEN WHEN BLOOD-BRAIN BARRIER INTEGRITY IS LOST. Neuro-Oncology, 2020, 22, ii68-ii68.	1.2	0
16	EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER. Neuro-Oncology, 2020, 22, ii103-ii103.	1.2	0
17	DDRE-01. ACQUIRED AND INTRINSIC RESISTANCE TO VEMURAFENIB IN BRAFV600E-DRIVEN MELANOMA BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii61-ii61.	1.2	0
18	EXTH-31. INCREASING TUMOR TREATING FIELDS (TTFIELDS) EFFICACY BY TARGETING THE G2 CELL CYCLE CHECKPOINT WITH WEE1 OR CHK1 INHIBITORS IN GLIOBLASTOMA CELL LINES. Neuro-Oncology, 2020, 22, ii93-ii93.	1.2	0

#	Article	IF	Citations
19	RBIO-05. MITOTIC ENRICHMENT AS AN EFFICIENT STRATEGY TO RADIOSENSITIZE GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii193-ii193.	1.2	0
20	<scp>SLC</scp> 1A3 contributes to Lâ€asparaginase resistance in solid tumors. EMBO Journal, 2019, 38, e102147.	7.8	41
21	EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 4351-4362.	7.0	33
22	Abstract LB-255: Acquired and intrinsic resistance to vemurafenib in BRAF^{v600e}-driven melanoma brain metastases. , 2019, , .		0
23	Abstract 4419: Cell cycle analysis during TTF to exploit novel targets for increasing treatment efficacy. , 2019, , .		0
24	Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of Extracellular Vesicles, 2018, 7, 1446660.	12.2	64
25	Serum Testosterone by Liquid Chromatography Tandem Mass Spectrometry for Routine Clinical Diagnostics. Methods in Molecular Biology, 2018, 1730, 93-102.	0.9	7
26	Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Bloodâ€“Brain Barrier Using Elacridar and ¹¹C-Erlotinib PET. Journal of Nuclear Medicine, 2018, 59, 973-979.	5.0	19
27	The impact of Pâ€glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. International Journal of Cancer, 2018, 142, 381-391.	5.1	55
28	ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Investigational New Drugs, 2018, 36, 380-387.	2.6	8
29	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50.	1.2	0
30	ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. Molecular Pharmaceutics, 2018, 15, 5236-5243.	4.6	20
31	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	7.0	30
32	An Experimenterâ€™s Guide to Glioblastoma Invasion Pathways. Trends in Molecular Medicine, 2018, 24, 763-780.	6.7	86
33	Buparlisib is a brain penetrable pan-PI3K inhibitor. Scientific Reports, 2018, 8, 10784.	3.3	52
34	Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. British Journal of Cancer, 2018, 118, 1586-1595.	6.4	29
35	DIPG-04. INHIBITION OF AXL SENSITIZES DIFFUSE INTRINSIC PONTINE GLIOMA TO CYTOTOXIC THERAPIES. Neuro-Oncology, 2018, 20, i49-i49.	1.2	0
36	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia, 2018, 20, 710-720.	5.3	84

#	Article	IF	Citations
37	A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clinica Chimica Acta, 2017, 469, 130-135.	1.1	15
38	The G2 checkpointâ€"a nodeâ€based molecular switch. FEBS Open Bio, 2017, 7, 439-455.	2.3	36
39	Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness. Cell Reports, 2017, 20, 48-60.	6.4	55
40	PI3Kâ€"mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models. Clinical Cancer Research, 2017, 23, 1286-1298.	7.0	56
41	Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar. Drug Delivery and Translational Research, 2017, 7, 125-131.	5.8	9
42	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8.	1.2	0
43	BCRP expression in schwannoma, plexiform neurofibroma and MPNST. Oncotarget, 2017, 8, 88751-88759.	1.8	4
44	Have we considered all barriers to mammalian target of rapamycin inhibition as treatment for diffuse intrinsic pontine glioma?. Translational Cancer Research, 2017, 6, S1431-S1434.	1.0	0
45	HG-52MELK INHIBITION AS A POTENTIAL TREATMENT FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2016, 18, iii59.1-iii59.	1.2	0
46	Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature, 2016, 530, 490-494.	27.8	202
47	Neurobiological changes by cytotoxic agents in mice. Behavioural Brain Research, 2016, 299, 19-26.	2.2	36
48	Strategies to target drugs to gliomas and CNS metastases of solid tumors. Journal of Neurology, 2016, 263, 428-440.	3.6	14
49	<scp>ABCB</scp>1 and <scp>ABCG</scp>2 restrict the brain penetration of a panel of novel <scp>EZH</scp>2â€inhibitors. International Journal of Cancer, 2015, 137, 2007-2018.	5.1	57
50	Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 207-219.	4.3	11
51	Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. Cell Reports, 2015, 10, 383-397.	6.4	70
52	Overcoming the bloodâ€"brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates, 2015, 19, 1-12.	14.4	706
53	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drugâ€"Drug Interactions in Vivo. Molecular Pharmaceutics, 2015, 12, 4259-4269.	4.6	32
54	P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Investigational New Drugs, 2015, 33, 1012-1019.	2.6	68

#	Article	IF	Citations
55	Cognitive impact of cytotoxic agents in mice. Psychopharmacology, 2015, 232, 17-37.	3.1	53
56	Abstract 3607: Loss-of-function screens using haploid KBM7 and HAP1 cells to identify mechanisms of anti-cancer drug resistance. , 2015, , .		0
57	Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101). PLoS ONE, 2014, 9, e82331.	2.5	207
58	â€œEffect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183â€• Investigational New Drugs, 2014, 32, 1083-1095.	2.6	11
59	In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. International Journal of Cancer, 2014, 135, 1700-1710.	5.1	43
60	OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice. Molecular Cancer Therapeutics, 2014, 13, 492-503.	4.1	33
61	ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research, 2014, 20, 2703-2713.	7.0	105
62	Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 913-914, 129-136.	2.3	6
63	Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging and Behavior, 2013, 7, 453-459.	2.1	118
64	Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene, 2013, 32, 1539-1548.	5.9	55
65	Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. European Journal of Cancer, 2013, 49, 2059-2064.	2.8	19
66	Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Investigational New Drugs, 2013, 31, 1125-1135.	2.6	24
67	Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues. Clinical Cancer Research, 2013, 19, 2084-2095.	7.0	48
68	Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Metâ€“driven Pancreatic Carcinoma. Cancer Research, 2013, 73, 6745-6756.	0.9	79
69	Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. Journal of the National Cancer Institute, 2013, 105, 1322-1331.	6.3	94
70	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Bloodâ€“Brain Barrier without restriction by ABCB1 and ABCG2. International Journal of Cancer, 2013, 133, 1222-1233.	5.1	26
71	Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncology, 2013, 2, 271-288.	3.0	21
72	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications, 2013, 4, 1908.	12.8	310

#	Article	IF	Citations
73	Abstract 966: Effect of ABC drug transporters (BCRP, MDR1, MRP2) on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA .. , 2013, , .		0
74	Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 901, 9-17.	2.3	6
75	From Mouse to Man: Predictions of Human Pharmacokinetics of Orally Administered Docetaxel From Preclinical Studies. Journal of Clinical Pharmacology, 2012, 52, 370-380.	2.0	4
76	EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors. PLoS ONE, 2012, 7, e45248.	2.5	24
77	Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Investigational New Drugs, 2012, 30, 443-449.	2.6	135
78	Abstract 5687: Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer. , 2012, , .		10
79	Abstract 5718: Implementation of Î¼-Image Guided Radio-Therapy in the treatment of experimental glioma mouse models: Assessment of the potential of agents that interfere with DNA repair. , 2012, , .		0
80	High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 3823-3831.	2.3	4
81	Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice. Investigational New Drugs, 2011, 29, 768-776.	2.6	20
82	Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast) Tj ETQq0 0 0 rgBT /Overlock 10 T 7-Hydroxymethotrexate. Drug Metabolism and Disposition, 2011, 39, 1338-1344.	3.3	48
83	High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel. Clinical Cancer Research, 2011, 17, 294-301.	7.0	49
84	Abstract LB-210: Impact of ABC-transporters in the blood-brain barrier on the efficacy of the PARP inhibitor ABT-888 against transplanted and spontaneous murine brain tumors. , 2011, , .		0
85	Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational New Drugs, 2010, 28, 145-155.	2.6	12
86	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. Cancer Research, 2010, 70, 1700-1710.	0.9	76
87	Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies. Clinical Cancer Research, 2010, 16, 3431-3441.	7.0	52
88	Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7257-7262.	7.1	182
89	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide. Clinical Cancer Research, 2010, 16, 130-140.	7.0	79
90	Abstract 5537: GSH-conjugation improves efficacy of Doxil against intracranial xenografts. , 2010, , .		3

#	Article	IF	Citations
91	Abstract LB-49: ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888. , 2010, , .		1
92	Abstract 4187: A rapid and robust transgenic high-grade glioma mouse model for therapy-intervention studies. , 2010, , .		0
93	Abstract LB-301: The impact of Abcb1 and Abcg2 on the brain penetration of PI3K-mTOR inhibitors. , 2010, , .		0
94	Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo. Clinical Cancer Research, 2009, 15, 3084-3093.	7.0	87
95	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Molecular Cancer Therapeutics, 2009, 8, 3350-3359.	4.1	74
96	Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743). Current Clinical Pharmacology, 2009, 4, 38-42.	0.6	12
97	A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine. Clinical Cancer Research, 2009, 15, 3574-3582.	7.0	101
98	Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. Cancer Research, 2009, 69, 8996-9002.	0.9	88
99	Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 2009, 9, 444.	2.6	166
100	Tumor microvasculature supports proliferation and expansion of gliomaâ€propagating cells. International Journal of Cancer, 2009, 125, 1222-1230.	5.1	53
101	Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clinical and Experimental Metastasis, 2009, 26, 171-178.	3.3	28
102	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational New Drugs, 2009, 27, 31-40.	2.6	132
103	Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3549-3555.	2.3	7
104	High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treatment Reviews, 2009, 35, 714-723.	7.7	56
105	Abstract A148: Palomid 529, a dual mTor1/2 inhibitor, efficiently penetrates the bloodâ€brain barrier and may be an attractive agent for treatment of glioblastoma. , 2009, , .		1
106	Magnetic resonance imagingâ€based detection of glial brain tumors in mice after antiangiogenic treatment. International Journal of Cancer, 2008, 122, 1981-1986.	5.1	51
107	Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behavioural Brain Research, 2008, 186, 168-175.	2.2	209
108	Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice. Drug Metabolism and Disposition, 2008, 36, 1606-1615.	3.3	29

#	Article	IF	Citations
109	Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. British Journal of Cancer, 2008, 98, 1784-1789.	6.4	56
110	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition inin vitroandin vivopharmacokinetic studies employing Bcrp1â^'/â^'/Mdr1a/1bâ^'/â^' (triple-knockout) and wild-type mice. Molecular Cancer Therapeutics, 2008, 7, 2280-2287.	4.1	183
111	Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate. Clinical Cancer Research, 2008, 14, 8152-8160.	7.0	56
112	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12117-12122.	7.1	279
113	In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics, 2007, 6, 3307-3313.	4.1	27
114	P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan. Clinical Cancer Research, 2007, 13, 6440-6449.	7.0	252
115	Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. BioTechniques, 2007, 43, S7-S13, S30.	1.8	121
116	Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 747-754.	1.7	43
117	Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 1191-1200.	1.7	20
118	Bmi1 Controls Tumor Development in an Ink4a/Arf-Independent Manner in a Mouse Model for Glioma. Cancer Cell, 2007, 12, 328-341.	16.8	264
119	Trabectedin (ET-743, Yondelisâ„¢) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational New Drugs, 2007, 25, 1-7.	2.6	18
120	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation, 2007, 117, 3583-3592.	8.2	210
121	Bloodâ€"brain barrier and chemotherapeutic treatment of brain tumors. Expert Review of Neurotherapeutics, 2006, 6, 1199-1209.	2.8	124
122	The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Cancer Chemotherapy and Pharmacology, 2006, 57, 819-825.	2.3	10
123	Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies UsingMrp2(Abcc2) Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 319-327.	2.5	146
124	Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics. Clinical Cancer Research, 2006, 12, 6125-6132.	7.0	88
125	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International Journal of Cancer, 2005, 116, 824-829.	5.1	189
126	Metabolism of docetaxel in mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 299-306.	2.3	14

#	Article	IF	Citations
127	Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry, 2005, 382, 1484-1490.	3.7	23
128	The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients. Cancer Research, 2005, 65, 2577-2582.	0.9	338
129	Experimental models to evaluate the role of P-glycoprotein in the bloodâ€“brain tumor barrier. International Congress Series, 2005, 1277, 123-130.	0.2	0
130	The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemotherapy and Pharmacology, 2004, 53, 173-178.	2.3	85
131	Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investigational New Drugs, 2004, 22, 219-229.	2.6	71
132	A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. Journal of Mass Spectrometry, 2004, 39, 1506-1512.	1.6	31
133	Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Analytical Biochemistry, 2004, 324, 11-15.	2.4	12
134	Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. Cancer Research, 2004, 64, 5804-5811.	0.9	222
135	Modulation of the bloodâ€“brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treatment Reviews, 2004, 30, 415-423.	7.7	174
136	Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples. Laboratory Animals, 2003, 37, 181-187.	1.0	37
137	P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. British Journal of Cancer, 2003, 89, 1776-1782.	6.4	39
138	Metabolism of paclitaxel in mice. Anti-Cancer Drugs, 2003, 14, 203-209.	1.4	14
139	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research, 2003, 63, 1339-44.	0.9	89
140	Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clinical Cancer Research, 2003, 9, 2849-55.	7.0	183
141	Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemotherapy and Pharmacology, 2002, 49, 119-125.	2.3	57
142	A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemotherapy and Pharmacology, 2002, 50, 16-24.	2.3	10
143	A population pharmacokinetic model for Cremophor EL using nonlinear mixed-effect modeling: model building and validation. British Journal of Clinical Pharmacology, 2002, 53, 552P-553P.	2.4	1
144	Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Research, 2002, 62, 6158-64.	0.9	116

#	Article	IF	Citations
145	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 2002, 1, 417-25.	4.1	371
146	The importance of drug-transporting P-glycoproteins in toxicology. Toxicology Letters, 2001, 120, 31-41.	0.8	72
147	The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anti-Cancer Drugs, 2001, 12, 351-358.	1.4	29
148	Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry. Fresenius' Journal of Analytical Chemistry, 2001, 369, 442-445.	1.5	15
149	A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemotherapy and Pharmacology, 2001, 47, 347-354.	2.3	39
150	Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography. Biomedical Applications, 2001, 763, 201-206.	1.7	9
151	Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. British Journal of Cancer, 2001, 84, 604-610.	6.4	35
152	The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. British Journal of Cancer, 2001, 85, 1472-1477.	6.4	68
153	Phase I and Pharmacokinetic Study of Oral Paclitaxel. Journal of Clinical Oncology, 2000, 18, 2468-2475.	1.6	83
154	Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anti-Cancer Drugs, 2000, 11, 813-820.	1.4	26
155	Cremophor EL pharmacokinetics in a phase I study of paclitaxel (TaxolÂ®) and carboplatin in non-small cell lung cancer patients. Anti-Cancer Drugs, 2000, 11, 687-694.	1.4	9
156	Modulation of oral bioavailability of anticancer drugs: from mouse to man. European Journal of Pharmaceutical Sciences, 2000, 12, 103-110.	4.0	125
157	The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Investigational New Drugs, 2000, 18, 231-241.	2.6	43
158	Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. British Journal of Cancer, 1999, 79, 1454-1461.	6.4	11
159	Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion. Anti-Cancer Drugs, 1999, 10, 17-24.	1.4	18
160	Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. Journal of Clinical Investigation, 1999, 104, 1441-1447.	8.2	314
161	Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. Biomedical Applications, 1998, 712, 129-143.	1.7	62
162	High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma. Biomedical Applications, 1998, 719, 251-257.	1.7	5

#	Article	IF	Citations
163	Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs, 1998, 9, 1-17.	1.4	125
164	Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. Anti-Cancer Drugs, 1998, 9, 665-763.	1.4	7
165	The Functional Role of P-Glycoprotein in the Bloodâ€“Brain Barrier. Journal of Pharmaceutical Sciences, 1997, 86, 881-884.	3.3	119
166	The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemotherapy and Pharmacology, 1997, 40, 330-334.	2.3	10
167	Tissue distribution, metabolism and excretion of paclitaxel in mice. Anti-Cancer Drugs, 1996, 7, 78-86.	1.4	106
168	Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. Biomedical Applications, 1996, 681, 355-362.	1.7	34
169	Monitoring Carboplatin Concentrations in Saliva. Therapeutic Drug Monitoring, 1995, 17, 465-470.	2.0	18
170	Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. Biomedical Applications, 1995, 664, 383-391.	1.7	63
171	Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemotherapy and Pharmacology, 1995, 36, 299-304.	2.3	52
172	Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. Biomedical Applications, 1994, 652, 51-58.	1.7	4
173	Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77, 491-502.	28.9	2,163
174	Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1994, 33, 425-434.	2.3	2
175	Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1994, 33, 425-434.	2.3	0
176	Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemotherapy and Pharmacology, 1993, 32, 286-292.	2.3	19
177	Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography. Investigational New Drugs, 1993, 11, 141-150.	2.6	21
178	Analytical methods for the determination of vinca alkaloids in biological specimens: A survey of the literature. Journal of Pharmaceutical and Biomedical Analysis, 1991, 9, 1077-1082.	2.8	22
179	Intratumoural administration of cisplatin in slow-release devices: II. pharmacokinetics and intratumoural distribution. Cancer Chemotherapy and Pharmacology, 1991, 27, 347-353.	2.3	48
180	Drug Repurposing Screen on Patient-Derived Organoids Identifies New Therapeutic Drug Combination Against KRAS Mutant Colon Cancer. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
181	Indisulam Synergizes With Palbociclib to Induce Senescence Through Inhibition of CDK2 Kinase Activity. SSRN Electronic Journal, 0, , .	0.4	0